Table 3.

Allergic asthma models in guinea pigs

Model	Description	Administered dose
Sutovska et al. 2016 [96]	• Model of 20 days • Sensitization i.p. y s.c. in day 1 and day 3 • Allergen challenges in days 9, 12, 15, 18 and 20 with inhaled OVA	▲ 5 mg OVA + 1 mg/ml Al(OH)3/SSF i.p in day 1 ⬤ 5 mg OVA/1 ml SSF s.c. in day 3 Inhaled OVA 1–2 min
Medvedova et al. 2015 [97]	• Model of 21 days • Sensitization i.p. and s.c. in day 1 • Sensitization i.p in day 3 • Inhaled OVA on days 14 and 21	▲ 1% OVA solution in aqua pro inyectione, 0.5 ml i.p. and 0.5 ml s.c on day 1 and 1 ml i.p. in day 3 ⬤ Inhaled OVA by 30 s
Lowe et al. 2017 [26]	• Model of 21 days • Sensitization i.p. on days 1, 4 and 7 • Inhaled OVA in day 21	▲ 150 µg OVA + 100 mg Al(OH)3 in 1 ml SSF in sensitization ⬤ 300 µg OVA/1 ml SSF on inhaled OVA
Franova et al. 2012 [98]	• Model of 21 days • Sensitization i.p. and s.c. on day 1 • Repead i.p. OVA inyections every 3 days • Nebulized OVA for the last 5 days	▲ 5 mg OVA + 1 mg Al(OH)3 i.p. and 5 mg OVA on 1 ml SSF s.c ⬤ 1% OVA in 0.9% sterile sodium chloride solution for nebulized OVA
Antwi et a. 2017 [70]	• Model of 30 days • Sensitization i.p. on day 1 • Antigenic reforcement i.p. on day 14 • Challenge with inhaled OVA from day 21 to day 30	▲ 2 mg OVA enmulsified in 10 mg ⬣ Al(OH)3 dissolved in 10 ml SSF i.p and 1 mg OVA dissolved in SSF i.p ⬤ 1% OVA w/v dissolved in PBS inhaled
Pazhoohan et al. 2017 [99]	• Model of 34 days • Nebulized OVA every 3 days for 5 weeks	⬤ 1 mg OVA/1 ml NaCl 0.9% on days 1,4,7,10 and 13 ⬤ 2.5 mg OVA/1 ml NaCl 0.9% on days 16, 19 and 22 ⬤ 5 mg OVA/1 ml NaCl 0.9% on day 25 and 28 ⬤ 10 mg OVA/1 ml NaCl 0.9% on day 31 and 34 ⬤ All inhaled OVA by 10 min time
Bazán-Perkins et al. 2009 [33]	• Model of 35 days • Sensitization i.p. and s.c. on day 1 • Antigenic reforcement with nebulized OVA on day 8 • Inhaled antigen on days 15, 25, 35 • Model of 125 days • Sensitization i.p. and s.c. on day 1 • Antigenic reforcement with nebulized OVA on day 8 • Inhaled antigen starting from day 15, every ten days until day 125	▲ 0.6 mg/ml OVA + 1 mg/ml Al(OH)3 dispersed in SSF ⬣ 3 mg OVA/ml SSF nebulized by 5 min ⬤ From day 15, 1 mg OVA/1 ml SSF and the subsequent challenges, 0.5 mg OVA/1 ml SSF nebulized during 1 min
Jiao et al. 2015 [95]	• Model of 65 days • Cyclophosphamide inyections i.p. on day 1 • Sensitization i.p. on day 2 • Antigenic reforcement i.p. on day 23 • Inhaled OVA on days 44 and 65	▲ Cyclophosphamide 30 mg/kg i.p. 2 mg OVA + 100 mg Al(OH)3 i.p ⬣ 0.1 mg OVA + 100 mg Al(OH)3 i.p ⬤ 10 mg/ml OVA aerosol for 90 s

i.p.: intraperitoneal, s.c.: subcutaneous